Polidocanol Patent Expiration
Polidocanol is used for treating varicose veins. It was first introduced by Chemische Fabrik Kreussler & Co. Gmbh
Polidocanol Patents
Given below is the list of patents protecting Polidocanol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Varithena | US9480652 | Aerosol valve | May 12, 2032 | Provensis |
| Varithena | US7814943 | Apparatus and method for dispensing foam | Nov 19, 2027 | Provensis |
| Varithena | US7731986 | Therapeutic foam |
Nov 17, 2024
(Expired) | Provensis |
| Varithena | US8122917 | Apparatus and method for dispensing foam |
Sep 09, 2024
(Expired) | Provensis |
| Varithena | US6846412 | Combination filter assembly |
Jul 19, 2022
(Expired) | Provensis |
| Varithena | US6572873 | Generation of therapeutic microfoam |
May 26, 2020
(Expired) | Provensis |
| Varithena | US6942165 | Generation of therapeutic microfoam |
May 26, 2020
(Expired) | Provensis |
| Varithena | US7025290 | Generation of therapeutic microfoam |
May 26, 2020
(Expired) | Provensis |
| Varithena | US7357336 | Generation of therapeutic microfoam |
May 26, 2020
(Expired) | Provensis |
| Varithena | US7604185 | Generation of therapeutic microfoam |
May 26, 2020
(Expired) | Provensis |
| Varithena | US7842282 | Generation of therapeutic microfoam |
May 26, 2020
(Expired) | Provensis |
| Varithena | US7842283 | Generation of therapeutic microfoam |
May 26, 2020
(Expired) | Provensis |
| Varithena | US8323677 | Therapeutic foam |
May 26, 2020
(Expired) | Provensis |
| Varithena | US8734833 | Therapeutic foam |
May 26, 2020
(Expired) | Provensis |
| Varithena | USRE40640 | Injectable microfoam containing a sclerosing agent |
Oct 14, 2016
(Expired) | Provensis |
| Varithena | USRE38919 | Injectable microfoam containing a sclerosing agent |
Oct 14, 2014
(Expired) | Provensis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Polidocanol's patents.
Latest Legal Activities on Polidocanol's Patents
Given below is the list recent legal activities going on the following patents of Polidocanol.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed Critical
| 24 Jun, 2024 | US9480652 |
| Expire Patent Critical
| 01 Apr, 2024 | US8122917 |
| Maintenance Fee Reminder Mailed Critical
| 16 Oct, 2023 | US8122917 |
| Interim Patent Term Extension Granted Critical
| 28 Feb, 2023 | US7357336 |
| Expire Patent Critical
| 04 Jul, 2022 | US8734833 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 May, 2022 | US7842283 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 May, 2022 | US7842282 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Apr, 2022 | US7814943 |
| Interim Patent Term Extension Granted Critical
| 07 Mar, 2022 | US7357336 |
| Maintenance Fee Reminder Mailed Critical
| 17 Jan, 2022 | US8734833 |
Polidocanol's Family Patents
